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CASE REPORT
Insulinoma, a functioning neoplasm derived from
the beta cells of the pancreas, is a rare tumor. The
incidence in the general population is about 
4 cases per million a year.1 The disorder usually
occurs in people who are otherwise healthy.
Hypoglycemia in patients with diabetes is nearly
always attributable to oral hypoglycemic agents
or insulin. Although insulinoma in a patient with
pre-existing diabetes is extraordinarily rare, it may
occur. We report such a case.
Case Report
A 74-year-old woman with rheumatoid arthritis
and type 2 diabetes was admitted for evaluation
of frequent hypoglycemic episodes manifested
by dizziness and diaphoresis. Her diabetes had
been diagnosed in 1999 and was treated with gli-
clazide, 160 mg/day. She had also been taking
prednisolone 5 mg/day, for 3 to 4 years for her
arthritis, as well as using over-the-counter topical
steroids for eczema. In 2002, she experienced an
initial episode of hypoglycemia, and the dose of
gliclazide was reduced. However, she continued
to have frequent hypoglycemic episodes, despite
repeated dose reductions and finally discontined
the drug in February 2005. Two months later, her
fasting plasma glucose was 33 mg/dL. She was
also found to have secondary adrenal insuffici-
ency, with plasma cortisol and adrenocorticotropic
hormone (ACTH) levels of 1.35 μg/dL (normal,
5.00–20.00μg/dL) and 1.07 pg/mL (normal, 9.00–
52.00 pg/mL), for which cortisone acetate was
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prescribed. Episodic hypoglycemia persisted. In
November 2005, that is, approximately 9 months
after discontinuation of glicazide, her fasting
plasma glucose was 22 mg/dL and plasma insulin
and C-peptide levels were 32.7 μIU/mL (normal,
< 30.0 μIU/mL) and 17.60 ng/mL (normal, 1.00–
3.00 ng/mL). The insulin and C-peptide levels
were measured by radioimmunoassay using a
DPC GAMBYT-CR gamma counter instrument.
We did not measure plasma sulfonylurea levels
as we were confident the patient had indeed
stopped taking glicazide. Thus, endogenous hy-
perinsulinism was confirmed, accounting for her
hypoglycemia, and she was admitted for further
management.
On admission in December 2005, her weight
was 70 kg and her height was 154 cm (body mass
index, 30 kg/m2). Her laboratory profile was as
follows: fasting plasma glucose, 11 mg/dL; free-T4,
2.20 ng/dL (normal, 0.80–2.00 ng/dL); thyroid
stimulating hormone (TSH), 2.14 μIU/mL (nor-
mal, 0.25–4.00μIU/mL); 8AM cortisol, 9.92μg/dL
(normal, 5.00–25.00 μg/dL); ACTH, 28.30 pg/mL
(normal, 9.00–52.00 pg/mL); HbA1c, 4.3% (4.2–
6.4%). A test for anti-insulin antibodies was neg-
ative. Transabdominal ultrasonography (Figure 1)
and magnetic resonance imaging (MRI) scan
(Figure 2) showed a 2.0 × 2.2-cm well-defined
soft tissue mass in the head of the pancreas. At
surgery, a 2.0 × 2.0 × 2.2-cm well-circumscribed,
dark-reddish tumor was successfully enucleated
(Figure 3). The histopathologic diagnosis was in-
sulinoma (Figure 4). After surgery, the patient ex-
perienced no further hypoglycemia and indeed,
required insulin to treat her diabetes.
Discussion
The criteria for diagnosing insulinoma in patients
with diabetes includes the following: (1) develop-
ment of Whipple’s triad;2 (2) presence of endoge-
nous hyperinsulinism; (3) exclusion of other
causes of hypoglycemia; and (4) amelioration of
hypoglycemia after resection of the tumor. When
a patient with diabetes presents with hypoglyce-
mia, the most common explanation is over treat-
ment or inadequate food intake. Our patient,
however, had hyperinsulinemic hypoglycemia even
Figure 1. Abdominal echo reveals a 2.2-cm, well-defined,
isoechoic nodular lesion in the uncinate process of the
pancreas (arrow).
Figure 2. Magnetic resonance imaging shows a 2.0-cm,
well-defined mass in the head of the pancreas that enhances
with gadolinium–diethylenetriamine (arrow).
Figure 3. A round, 2.0 × 2.0 × 2.2-cm, well-circumscribed,
dark-reddish tumor enucleated at surgery.
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when completely off hypoglycemic agents. In ad-
dition to insulinoma, the differential diagnoses of
hyperinsulinemic hypoglycemia include familial
persistent hyperinsulinemic hypoglycemia, primary
islet-cell hyperplasia, and noninsulinoma pancre-
atogenous hypoglycemic syndrome. Our patient’s
findings clearly fulfilled the criteria for insulinoma,
which was demonstrated by MRI.
Insulinoma is a rare endocrine tumor derived
from pancreatic islet cells that produces excessive
amounts of insulin. Such tumors are usually small,
solitary, benign, well-circumscribed, and may occur
anywhere in the pancreas.3 Patients usually present
with symptoms of neuroglycopenia such as con-
fusion, visual changes, unusual behavior and with
sympathoadrenal symptoms such as palpitation,
sweating and tremor.4 A presumptive diagnosis
of insulinoma is made when there is evidence of
endogenous insulin secretion that is inappropri-
ately high for a given glucose level in a patient
who is not taking an insulin secretagogue. Surgery
is the only curative treatment currently available,
although streptozotocin or diazoxide may be used
to control the disease when the tumor cannot be
completely removed. However, Arioglu et al5 re-
ported a patient with a proinsulin-secreting in-
sulinoma initially presenting with symptomatic
hypoglycemia. The tumor was not resected and
was treated with diazoxide. Eventually, the patient
developed clinical diabetes.
In contrast to this very rare beta-cell tumor,
diabetes is an exceedingly common metabolic dis-
order, associated with various degrees of beta-cell
dysfunction. The prevalence of type 2 diabetes in
adults is reported to be 4.9–9.2% in Taiwan.6 As
mentioned above, when a patient being treated
for diabetes becomes hypoglycemic, it is almost
always because of the treatment, whether with
oral hypoglycemic agents or insulin. It is difficult
to know whether there is any pathogenetic rela-
tionship between diabetes and insulinoma. Several
older reports suggested an association between
insulinoma and a family history of diabetes.7,8 In
a series from the Mayo Clinic, 30% of patients
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Figure 4. (A) Pathology specimen demonstrating tumor cells with abundant eosinophilic cytoplasm (arrow) and blank-
looking nuclei (arrowhead) arranged in a trabecular pattern (hematoxylin & eosin, 400×). On immunohistochemical staining,
the tumor cells are positive for: (B) chromogranin; (C) synaptophysin; and (D) neuron-specific enolase.
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with insulinoma had a family history of diabetes.8
Streptozotocin destroys beta cells and may thus
cause diabetes. Experiments in rats demonstrate
that the combination of nicotinamide and strep-
tozotocin can induce insulinoma,9 although it 
is hard to see what bearing this would have on
naturally occurring disease in humans.
The coincidence of insulinoma and diabetes
is so rare that there are only a few individual case
reports. Only a few well-documented cases of in-
sulinoma associated with type 2 diabetes10–16 and
one with type 1 diabetes17 have been published
in the past 50 years. Looking at it from a different
angle, the incidence of diabetes among patients
with insulinoma is also quite low. Among 313 con-
firmed cases of insulinoma at the Mayo Clinic be-
tween 1927 and 1992, there was only one patient
with pre-existing diabetes.11 In a similar review
from Japan, of 443 cases of insulinoma between
1976 and 1990, only one patient had diabetes too.
In that particular case, the insulinoma was malig-
nant.18 The incidence and prevalence of insulino-
ma in Taiwan is unknown. However, we reviewed
23 cases of insulinoma seen at our institution
between July 1984 and March 2006 and only the
patient we are reporting here had diabetes.
Previous reports of the co-occurrence of these
two disorders are difficult to assess because other
associated diseases that might cause hypoglyce-
mia such as renal failure19 or liver cirrhosis20 have
not been mentioned. Also, earlier cases relied on
less accurate diagnostic techniques than those
presently available.
Our case demonstrates the current state of the
art in which endogenous hyperinsulinism can be
confirmed by an elevated plasma insulin and 
C-peptide level in the absence of a sulfonylurea
and the tumor can be localized by any one of a
number of imaging techniques. Sapountzi et al21
first reported a case with insulinoma and con-
comitant diabetes in which continuous glucose
monitoring was an important diagnostic tool.
This method, being reliable, safe and easy to per-
form, is worthwhile considering the possibility to
detect unusual causes of hypoglycemia, including
insulinoma.
Patients with adrenal insufficiency may have
hypoglycemia. Our patient’s secondary adrenal in-
sufficiency was most likely caused by the predniso-
lone she took for her arthritis. Suppression of the
hypothalamic–pituitary axis by exogenous steroids
is thought to relate to the duration of therapy, the
highest dose and the total cumulative steroid dose.
However, it is difficult to accurately predict the
degree of adrenal suppression in any particular
patient. It is reported that those who take 5 mg/day
or less of prednisolone generally have an intact
hypothalamic–pituitary–adrenal axis.22 Although
our patient’s prednisolone dose was in this range,
she did have suppression of the axis. Perhaps there
may have been an additive effect from the topical
steroids she used for a skin condition. At any rate,
exogenous steroid therapy is the most likely ex-
planation for her secondary adrenal insufficiency.
There does not seem to be any connection between
this condition and her insulinoma.
In conclusion, hypoglycemia in a patient with
diabetes is almost invariably ascribed to the drugs
used to control hyperglycemia. However, in a pa-
tient who has dramatic improvement of diabetes
mellitus, particularly after withdrawal of all hypo-
glycemic treatment, an insulin-producing tumor
should be considered.
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